Newsstand Menu

Cracking the mystery behind a deadly brain cancer

Image of glioblastoma patient brain MRI
A series of brain MRIs from a glioblastoma patient with a tumor in the left frontal lobe. New research from Cold Spring Harbor Laboratory reveals an unprecedented therapeutic strategy for battling this aggressive cancer. Image: © Richman Photo –

image of the Harbor Transcript Magazine logo Summer 2023 edition

Print Friendly, PDF & Email

The brain cancer, glioblastoma, is a fierce and formidable opponent. Its millions of victims include Senator John McCain, President Biden’s son, Beau, and famed film critic Gene Siskel, to name just a few. Most patients succumb within two years and few make it past five, a statistic that hasn’t improved in decades due to lack of effective treatment options.

Image of Mills lab at the Darlene Carbone Brain Tumor Foundation's 2nd Annual Walk to support glioblastoma research
The Mills lab weathering the rain at the Darlene Carbone Brain Tumor Foundation’s 2nd Annual Walk to support glioblastoma research. Image: Darlene Carbone Brain Tumor Foundation

“The aggressiveness of glioblastoma is notorious,” says Cold Spring Harbor Laboratory (CSHL) Professor Alea Mills. “The norm is to do surgery, treat with harsh drugs, and just hope for the best.” But now, Mills and her colleagues have discovered in this deadly cancer a vulnerability, known as BRD8, that may finally lead to new treatment options and better patient outcomes.

The CSHL team recently solved a decades-old mystery surrounding glioblastoma’s aggressiveness by linking the BRD8 protein to another protein, named P53. A staple in the body’s natural cancer defenses, P53 prevents cells from overgrowing and turning into tumors. Almost all cancers depend on P53 becoming mutated and thus disabled. But weirdly, in the majority of glioblastoma cases, P53 is unscathed. “So why does this cancer act like P53 is broken?” asked CSHL postdoctoral fellow Xueqin Sun. This critical question led Mills’ team to discover that BRD8 had gone rogue in glioblastoma, crippling P53 in a completely new way.

BRD8 shuts down access to genes in chromosomes. If a gene is wound up tightly, it cannot be used—it’s as if it were “asleep.” Mills and her team revealed that BRD8 was inappropriately active in glioblastoma, keeping many of P53’s critical anticancer defenses at rest. When the researchers inactivated BRD8 via genome editing, P53’s “arsenal” suddenly woke up and began blocking tumor growth.

Illustration of BRD8 and P53 proteins
A model illustrating the relationship between the BRD8 and P53 proteins. When BRD8 is active, it can lock out P53 from activating cancer-preventing genes, resulting in glioblastoma.

“It’s like BRD8 is saying ‘NO ENTRY’ to P53’s tumor-preventing power, but when we hit BRD8 in the right way—go in there almost like a scalpel, but molecularly—the tumor is annihilated,” Mills explains. She and her team implanted tumor cells from glioblastoma patients into mice and watched the tumors grow in the brain. When BRD8 was inactivated, P53 was unlocked—the tumors stopped growing and the mice lived longer.

The finding suggests that drugs targeting the heart of BRD8 could work against glioblastoma. Mills hopes her team’s discovery will help turn this deadly brain cancer into a treatable disease and for the first time in a generation, extend the life expectancy of patients who are diagnosed with it.

Written by: Luis Sandoval, Communications Specialist | | 516-367-6826


Print Friendly, PDF & Email

Cancer Center Support Grant, Cold Spring Harbor Laboratory and Northwell Health Affiliation, National Institutes of Health, the Darlene Carbone Brain Tumor Foundation, the Bradley Zankel Foundation, the Edward Davis Foundation


Print Friendly, PDF & Email

Sun, X., et al., “BRD8 maintains glioblastoma by epigenetic reprogramming of the P53 network”, Nature, December 21, 2022. DOI: 10.1038/s41586-022-05551-x

Stay informed

Sign up for our newsletter to get the latest discoveries, upcoming events, videos, podcasts, and a news roundup delivered straight to your inbox every month.

  Newsletter Signup

Principal Investigator

Alea A. Mills

Alea A. Mills

Cancer Center Member
Ph.D., University of California, Irvine, 1997